TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Nigel Richardson, PhD
Senior Director CMC Analytical, Product Development & Supply, MST, R&D at GlaxoSmithKline

Profile

Nigel Richardson is a senior director in the CMC Analytical Division at GSK. He was awarded a PhD in synthetic organic chemistry from Exeter University. After nine years with Dow as a research analyst he moved to GSK as an analytical Team Leader within the Chemical Development division based in Stevenage, UK. Within GSK Dr Richardson has led the analytical activities from Phase I to commercialisation for Tykerb (breast cancer medicine) and led GSK’s oligonucleotide therapy for Duchenne Muscular Dystrophy into the final stages of development and regulatory submission. He has worked as chemistry lead in a team focused on oligonucleotide delivery. In his most recent position he had responsibility for a department focused on new analytical technology evaluation and deployment, PAT, chromatography platforms, LIMS/CDS systems and analytical automation.

Nigel Richardson, PhD's Network

Agenda Sessions

  • Trends in Developing Oligo-specific CMC Understanding by Exploiting Prior Knowledge

    , 17:00

Speakers at this event